CELLYAN BIOTECHNOLOGY CO-A

HKPDNASDAQ

🏆 #3896 by market capUS Equity

$0.41▼ $0.01 (−2.07%)

Live

1h—

24h▼ 2.1%

7d▲ 6.7%

14d▲ 3.8%

30d▼ 12.6%

1y▼ 64.0%

🏦Market Cap

$10M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $0.41 – $0.41
52-Week Range: $0.31 – $2.58
Volume: $2.11B
Avg Volume: $1.61B
Shares Outstanding: 23.5M
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $20M
Last Q Revenue: $7M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own HKPD

✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
✓Healthy economics — 64% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$20M▲ +48.8% YoY

Gross Margin (TTM)

64.3%▲ +3.1% YoY

Operating Income (TTM)

$4M▲ +48.8% YoY

Free Cash Flow (TTM)

$4M▲ +48.8% YoY

About CELLYAN BIOTECHNOLOGY CO-A

Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.

🦦